STOCK TITAN

OnKure Therapeutics (OKUR): ADAR1 reports 5.5% stake as GP falls below 5%

(Neutral)
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

OnKure Therapeutics, Inc. is the issuer of Class A common stock covered in this beneficial ownership report. Investment adviser ADAR1 Capital Management, LLC and its manager Daniel Schneeberger each report beneficial ownership of 2,238,684 shares of Class A common stock, representing 5.5% of the class based on 40,496,309 shares outstanding as of June 30, 2026. These shares include holdings by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC, and other separately managed accounts for which ADAR1 Capital Management acts as investment manager or sub-adviser.

ADAR1 Capital Management GP, LLC, as general partner of ADAR1 Partners, LP, reports beneficial ownership of 1,832,117 shares, or 4.5% of the class, and this amendment is identified as an exit filing solely for ADAR1 Capital Management GP, LLC as a 5% owner. All reporting persons disclose shared voting and dispositive power over their reported shares and no sole voting or dispositive power.

Positive

  • None.

Negative

  • None.
ADAR1 Capital Management beneficial ownership 2,238,684 shares (5.5%) Class A common stock of OnKure Therapeutics based on 40,496,309 shares outstanding as of June 30, 2026
ADAR1 Capital Management GP, LLC beneficial ownership 1,832,117 shares (4.5%) Class A common stock of OnKure Therapeutics through ADAR1 Partners, LP as of June 30, 2026
Daniel Schneeberger beneficial ownership 2,238,684 shares (5.5%) Indirect ownership via ADAR1 Capital Management entities and managed accounts as of June 30, 2026
Shares outstanding baseline 40,496,309 shares OnKure Therapeutics Class A common stock outstanding as of June 30, 2026 per Form 10-Q
ADAR1 Partners, LP holdings 1,832,117 shares Class A common stock held by ADAR1 Partners, LP included in reported positions as of June 30, 2026
Spearhead Insurance Solutions IDF, LLC holdings 299,150 shares Class A common stock included in ADAR1 Capital Management and Schneeberger beneficial ownership
Other separately managed accounts holdings 107,417 shares Class A common stock in accounts managed by ADAR1 Capital Management as of June 30, 2026
beneficially own financial
"may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP"
Beneficially own means having the economic rights and risks of a security—such as the right to receive dividends, sell the shares, or profit from price changes—whether or not your name appears on the official share register. Think of it like renting a car: you use it and reap the benefits even if the title lists someone else. Investors care because beneficial ownership determines who truly controls value, must be disclosed under securities rules, and can signal potential influence or trading activity that affects a stock’s price.
shared voting power financial
"Shared Voting Power 2,238,684.00"
Shared voting power occurs when two or more parties jointly have the right to vote or decide how a block of company shares is cast, like co-owners who must agree before moving a piece of furniture. Investors care because who controls voting rights affects board elections, major corporate decisions and takeover outcomes, and shared control can alter regulatory disclosures and the practical influence any holder has over a company’s direction and value.
shared dispositive power financial
"Shared Dispositive Power 2,238,684.00"
exit filing regulatory
"this filing is an exit filing solely for ADAR1 General Partner"
control person regulatory
"Mr. Schneeberger is filing this as a control person in respect of shares"
A control person is an individual or entity that can significantly influence a company’s decisions and direction through ownership, voting power, or contractual rights—think of them as the captain who can steer the ship. Investors care because a control person’s choices affect corporate strategy, board appointments, and transactions that can raise or lower a stock’s value, and they often carry additional legal responsibilities and disclosure requirements to protect other shareholders.
investment adviser financial
"ADAR1 Capital Management, an investment adviser as described in SS 240.13d-1(b)(1)(ii)(E)"
An investment adviser is a person or firm that professionally manages money and gives recommendations about buying, selling, or holding investments. Like a financial coach or guide, they have a legal duty to act in a client's best financial interest, so their advice, fees and potential conflicts can directly affect returns and risk — making their role important for investors who want informed, accountable help with portfolios.

FAQ

What percentage of OnKure Therapeutics (OKUR) does ADAR1 Capital Management report owning?

ADAR1 Capital Management, LLC reports beneficial ownership of 2,238,684 shares of OnKure Therapeutics Class A common stock, representing 5.5% of the outstanding class, based on 40,496,309 shares outstanding as of June 30, 2026.

How many OnKure Therapeutics (OKUR) shares does ADAR1 Capital Management GP, LLC beneficially own?

ADAR1 Capital Management GP, LLC reports beneficial ownership of 1,832,117 shares of OnKure Therapeutics Class A common stock, representing 4.5% of the class, through its role as general partner of ADAR1 Partners, LP as of June 30, 2026.

What is Daniel Schneeberger’s reported beneficial ownership in OnKure Therapeutics (OKUR)?

Daniel Schneeberger reports beneficial ownership of 2,238,684 shares of OnKure Therapeutics Class A common stock, equal to 5.5% of the outstanding shares, through his managerial roles over ADAR1 Capital Management entities and related managed accounts.

Why is this Schedule 13G/A significant for ADAR1 Capital Management GP, LLC and OnKure Therapeutics (OKUR)?

The amendment is designated as an exit filing solely for ADAR1 Capital Management GP, LLC, which now reports 4.5% beneficial ownership, indicating its holdings are below the 5% threshold that typically triggers Schedule 13G reporting.

What is the total number of OnKure Therapeutics (OKUR) shares outstanding used for these ownership calculations?

The reported ownership percentages are calculated using 40,496,309 shares of OnKure Therapeutics Class A common stock outstanding as of June 30, 2026, as disclosed in the company’s Form 10-Q for that period.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates





68277Q105

(CUSIP Number)
06/30/2026

(Date of Event Which Requires Filing of this Statement)


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 299,150 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 107,417 shares of Common Stock held by other separately managed accounts as of June 30, 2026. As the investment manager of ADAR1 Partners, LP and as the sub-advisor of Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above, ADAR1 Capital Management, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts. Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP as of June 30, 2026. As the general partner of ADAR1 Partners, LP, ADAR1 Capital Management GP, LLC may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP. Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026.


SCHEDULE 13G




Comment for Type of Reporting Person: Includes (i) 1,832,117 shares of Class A common stock, par value $0.0001 per share ("Common Stock") held by ADAR1 Partners, LP, (ii) 299,150 shares of Common Stock held by Spearhead Insurance Solutions IDF, LLC and (iii) 107,417 shares of Common Stock held by other separately managed accounts as of June 30, 2026. As the manager of ADAR1 Capital Management, LLC, and ADAR1 Capital Management GP, LLC, Mr. Schneeberger may be deemed to indirectly beneficially own securities held by ADAR1 Partners, LP, Spearhead Insurance Solutions IDF, LLC and the separately managed accounts referenced above. Based on 40,496,309 shares of Common Stock of OnKure Therapeutics, Inc. (the "Issuer") outstanding as of June 30, 2026, reported in the Issuer's Form 10-Q for the quarterly period ended June 30, 2026, filed with the Securities and Exchange Commission on August 4, 2026.


SCHEDULE 13G



ADAR1 Capital Management, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2026
ADAR1 Capital Management GP, LLC
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, Manager
Date:08/14/2026
Daniel Schneeberger
Signature:/s/ Daniel Schneeberger
Name/Title:Daniel Schneeberger, in his individual capacity
Date:08/14/2026